Related Experiment Video

Updated: Apr 12, 2026

Author Spotlight: Implementation of BIVA for Analyzing Disease Risk Factors in Patients with Low Body Cell Mass
07:44

Author Spotlight: Implementation of BIVA for Analyzing Disease Risk Factors in Patients with Low Body Cell Mass

Published on: July 14, 2023

1.8K

The rate of decrease in the disease activity of rheumatoid arthritis during treatment with adalimumab depends on the

Koei Oh1, Satoshi Ito, Megumi Unno

  • 1Department of Rheumatology, Niigata Rheumatic Center, 2) Department of Orthopaedic, Showa University Northern Yokohama Hospital, Japan.

Internal Medicine (Tokyo, Japan)
|May 8, 2015
PubMed
Abstract

Insights

Adalimumab (ADA) is more effective for rheumatoid arthritis when combined with methotrexate (MTX) at doses over 8 mg/week. Higher MTX doses correlate with better disease control and remission rates in ADA-treated patients.

Area of Science:

  • Rheumatology
  • Clinical Pharmacology
  • Immunology

Background:

  • Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation.
  • Adalimumab (ADA) is a biologic therapy used to manage RA symptoms.
  • Methotrexate (MTX) is a common co-administered drug in RA treatment.

Purpose of the Study:

  • To evaluate the efficacy of adalimumab (ADA) in rheumatoid arthritis (RA) patients.
  • To compare ADA efficacy with and without methotrexate (MTX).
  • To determine the impact of MTX dosage on ADA treatment outcomes.

Main Methods:

  • A cohort of 68 RA patients receiving ADA were analyzed.
  • Patients were categorized based on MTX dosage: <8 mg/week, 8 mg/week, and >8 mg/week.
  • Disease Activity Score (DAS28-ESR) and clinical remission rates were assessed over 24 weeks.

Main Results:

  • Patients on MTX showed significantly better outcomes than those without MTX (DAS28-ESR: 2.7 vs 4.2; remission: 48% vs 25%).
  • ADA continuation rates were higher in patients receiving MTX (90%) compared to those without (50%).
  • Higher MTX doses (>8 mg/week) correlated with more rapid DAS28-ESR reduction and higher remission rates (57% vs 36%).

Conclusions:

  • Adalimumab (ADA) demonstrates enhanced efficacy in rheumatoid arthritis when used with methotrexate (MTX).
  • A minimum MTX dose of >8 mg/week is associated with superior clinical outcomes.
  • Optimizing MTX dosage is crucial for maximizing ADA's therapeutic benefit in RA patients.

More Related Videos

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

1.4K
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

7.5K

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
800
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
712
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
523
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
602
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
465
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K